1 Surveillance for Antimicrobial Resistance and Preparation of an Enhanced Antibiogram at the Local Level janet hindler
2 At the conclusion of this talk, you will be able to Describe CLSI M39-A3 recommendations for preparing cumulative antibiograms. Discuss some problems in calculating %S statistics and how to address them. List points to consider when evaluating cumulative %S data.
3 CLSI M39-A3 Guideline Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data M39-A3 2009
4 CLSI M39-A3 Guideline describes preparation of a cumulative antibiogram report to be used to support clinical decisions re: empiric therapy of initial infections
5 Cumulative antibiogram Generally one big report, but increasing emphasis on segregating data to answer specific questions
6 What does it mean to be compliant with CLSI M39-A3? (1) Analyze/present data at least annually Include only final, verified results Include only species with 30 isolates Include diagnostic (not surveillance) isolates Include the 1 st isolate/patient, irrespective of body site overall antimicrobial susceptibility profile Include only drugs routinely tested Calculate %S (do not include %I)
7 What does it mean to be compliant with CLSI M39-A3? (2) Staphylococcus aureus list %S for all and MRSA subset Streptococcus pneumoniae list %S for cefotaxime / ceftriaxone / penicillin w/ meningitis and non-meningitis breakpoints list %S for penicillin w/ oral breakpoints, if appropriate Viridans streptococcus - list %S and list %I for penicillin
8 Special Circumstance (1) % Susceptible N Amx Cftrx Ctax Ery Lvx Pen (IV) Pen (oral) Sxt S. pneumoniae meningitis* nonmeningitis** %S calculated using: * meningitis breakpoints **non-meningitis breakpoints cont..
9 Special Circumstance.. S. pneumoniae %S (2) 1 Breakpoints differ for ceftriaxone, cefotaxime and penicillin based on diagnosis. 2 Susceptible breakpoint for S. pneumoniae in patients with meningitis is 0.5 µg/ml for ceftriaxone and cefotaxime and 0.06 µg/ml for penicillin. 3 Susceptible breakpoint for S. pneumoniae in patients with nonmeningitis infections is 1 µg/ml for ceftriaxone and cefotaxime and 2 µg/ml for penicillin. 4 Susceptible breakpoint for S. pneumoniae is 0.06 µg/ml for penicillin when penicillin is administered by the oral route.
10 Special Circumstance.. % Susceptible Option 1 N Clin Ery Ox Pen T-S T S Van All SA 1317* MRSA MSSA * All NOT sum of MRSA and MSSA because: analyzed 1 st /iso/patient from each subset, e.g., OX-R S. aureus 36 pts had both MRSA and MSSA CLSI M39-A3
11 Special Circumstance.. Option 2 % Susceptible N Clin Ery Ox* Pen T-S T S Van MRSA MSSA *68% of all S. aureus are oxacillin-s CLSI M39-A3
12 Exmp. combine 2 years of data when N is <30 isolates Morganella morgannii Year N %S Cipro # S %S Gent # S Total N %S = Total #S / Total N %S - 70 (28/40) - 88 (35/40) -
13 If you must report N <30, consider comment such as %S calculated from fewer than the standard recommendation of 30 isolates
14 Cumulative antibiogram data are impacted by Patient population served Culturing practices Antimicrobial susceptibility testing policies Temporal outbreaks Assumes individual susceptibility test results used for cumulative antibiogram are Final Verified Results!
15 Example: Healthcare facilities showing differences in %S for oxacillin and S. aureus %S oxacillin Facility type Geriatrics? Known MRSA outbreaks? Perform AST on all S. aureus? Facility #1 35% Tertiary care Yes Yes No Facility #2 50% Acute care No No Yes if comparing %S data, you must understand the basis of the data!
16 To interpret cumulative antibiogram, data you should know (1) Source of isolates Random? Special collection; any selection criteria? Patient demographics? Geographic region? Dates of collection? Fresh isolates? Frozen isolates? Could isolates be clonal?
17 To interpret cumulative data antibiogram, you should know (2) Laboratory testing Method used for organism identification and AST? Criteria used to define susceptible? All drugs tested on all isolates concurrently? Isolates tested by central lab or in individual labs? QC documented? Unusual results confirmed? Data analysis Eliminate duplicates? Does %S include %I? N (small N value has large 95% confidence interval)
18 What are the options for excluding duplicate patient isolates? Count one isolate of a given species / patient / year M39-A3 suggests 1 st isolate/patient Count duplicates after x days (e.g. 7, 30 days) elapsed since testing the previous isolate from a given patient Count duplicate isolates on a patient that have different results for one or more drugs (e.g., S to R, R to S) Count all isolates
19 How do various methods for excluding duplicates impact %S? P. aeruginosa - ciprofloxacin # isolates % Cipro-S 2.2 isolates/patient st iso/patient 30 days Phenotype All M39-A3 50 UCLA 2008
20 When might we examine more isolates than the 1 st isolate/patient? When data from additional isolates are needed to answer a specific question Examples: How many patients had MDR Acinetobacter baumannii? Were any S. aureus not susceptible to daptomycin?
21 What about MDR Acinetobacter baumannii? A. baumannii - meropenem 1.9 isolates/patient # isolates % Mero-S st iso/patient All 0 M39-A3 UCLA 2008
22 How many Acinetobacter baumannii were MDR? Category # Isolates # Patients Comments All # MDR???? 1 st st isolate/pt # MDR???? MDR only For 3/43 pts, MDR was not 1 st iso/pt MDR = R to: aminoglycosides; carbapenems; anti-pseudomonal cephalosporins, penicillins, fluoroquinolones UCLA 2008
23 What are some concerns for calculating %S? Not all drugs may be tested on each isolate of a given species When this occurs, comparing results for one drug against another may be misleading Selective testing of isolates from specific body sites
24 Concern: 1) separate panel for testing Enterobacteriaceae from urine; 2) testing large numbers of urine isolates can dilute data N Am Cz E. coli % Susceptible Cip Lvx Sxt Non-urine only Urine only NT 77 All Both cipro and levo tested on gram-neg (non-urine) panel; cipro tested only on urine panel CLSI M39-A3
25 Optional Report Strategy (include comment) N Am Cz % Susceptible Cip Lvx Sxt E. coli * 76 Levofloxacin tested on non-urine isolates only (N=292). Levofloxacin results should not be compared to results of other drugs, all of which were tested on all isolates (urine and non-urine, N=3636). CLSI M39-A3
26 Concern: reporting % VRE?? Protocols for AST of enterococci may vary among labs (UCLA tests sterile site isolates, urine isolates from inpatients, and on request) N Van % Susc Enterococcus spp. - bld Enterococcus spp. - all UCLA 2008
27 What about stratifying %S data to provide suggested empiric therapy recommendations for select patients / conditions? By specimen type or infection site By nursing unit or site of care By organism s s resistance characteristics By clinical service or patient population
28 Example of %S Data Stratification using cumulative antibiogram data to guide empiric therapy of acute uncomplicated urinary tract infections (UTIs)
29 Organisms Tested for AST UCLA 2008 (N = 15,645) E. coli NOT UR E. coli UR P. aeruginosa K. pneumoniae Other Other GP Other GN Enterococcus GN, gram-negative bacteria GP, gram-positive bacteria S. aureus
30 Managing Uncomplicated UTIs in Women Risk factors for resistance? Current or recent TMP-SMX or other antibiotic Recent hospitalization Recurrent UTI in past year No TMP-SMX resistance in community >20%? Yes Yes Use alternative agent: Fluoroquinolone (3 days) Or Nitrofurantoin (7 days) Fosfomycin (single dose) No TMP-SMX (3 days) Warren et al CID. 29:745. Warren et al CID. 29:745. Gupta, Hooton, and Stamm Ann Intern Med. 135:41.
31 Variability in Urine C&S Ordering Practices Clinical Scenario Probable uncomplicated UTI Previous treatment failure in older woman 1 No. (%) of general practitioners who said they would order C&S 165/278 (59%) 262/291 (90%) 1 more likely to have resistant organisms Hillier et al J Antimicrob Chemother. 58:1303. Hillier et al J Antimicrob Chemother. 58:1303. Patient with uncomplicated UTIs often not cultured!
32 E. coli Urine Isolates % S data from 2 facilities during similar time frame Data Source 10/11/04 1/31/05 CA university health care service 1 All pts. presenting with uuti symptoms Outpatients Cip UCLA Cumulative Antibiogram Report 2 2 %S from first isolate/pt (CLSI M39-A3) 3 Includes ER patients N 88 TMP-SMX Smith et al Clin Infect Dis. 46:689.
33 E. coli Urine Isolates %S 1 4 Patient Populations Category All patients Inpatients Outpatients yo female outpatients 2 N Am Cz Cip Fm T-S %S from first isolate/pt (CLSI M39-A3) 2 Includes ER patients UCLA 2008
34 E. coli Urine Isolates (N=998) yo Female Outpatients Resistance Profile N % No Resistance Am Am Sxt Am Cz Am Cip Sxt Am Cz Sxt Sxt Am Cip Am Cz Cip Sxt Drugs examined: Am, Cz, Cip,, Fm, Sxt Cip Other UCLA 2008
35 Example: empiric therapy policy change following clinical failure and review of cumulative antibiogram data Elderly male patient with cystitis seen in ER failed empiric ciprofloxacin Rx; previously empiric Rx successful Performed culture (previously no culture) which revealed cipro-r E. coli ER MD Question: what is cipro %S for urine isolates of E. coli from ER patients?
36 E. coli Urine Isolates %S ER vs. All Outpatients N Am Cz Cip Fm Sxt ER <65 yo ER 65 yo All Revised ER Policy; use cipro empirically only in patients <65 yo UCLA 2005
37 Stratifying %S Data for MDR Organisms If MDR (e.g., KPC) endemic, consider stratifying data (e.g., by unit or R mechanism) Minimize skewing of data Example: KPCs might be predominantly among ICU patients May not be seen in OB-GYN; single cumulative antibiogram would offer limited guidance for empiric therapy options for OB-GYN patients
38 Stratifying %S Data for MDR Organisms (e.g., ESBL, KPC) CLSI M39-A3
39 What about %S data for combinations of agents? Guide empiric therapy of infections where the likely causative organisms are best treated with combinations of antimicrobial agents Calculate %S to either (or both) of the two agents Does NOT imply synergy, antagonism or likely activity in vivo
40 P. aeruginosa % Susceptible* (N=726) Option 1 Cip Cftaz Mero Tob Cftaz +/or Cip Mero +/or Cip Cftaz +/or Tob Mero +/or Tob % S includes isolates that have any of these 3 profiles Cftaz S S R Tob S R S *analysis included 1 st isolate/patient UCLA 2008
41 P. aeruginosa (N=726 patients 1 ) Option 2 %S to 7 drugs and %S to either or both when 2 drugs are evaluated (%S for 2 drugs does NOT imply synergy, antagonism or likely activity in vivo) Ceftaz (74%) Mero (79%) Pip-taz 4 (69%) Cip (64%) Amik (94%) 2 98% Gent (80%) Tob (85%) Cip (64%) 1analysis included the most R result for each drug if patient had >1 isolate 2 %S for one drug - value in ( ) 3 %S for either or both drugs (e.g., %S to amik and/or ceftaz) UCLA used 16 µg/ml breakpoint for S
42 Patient JWR had 4 isolates of P. aeruginosa Isolate # Cip S R R R Gm R R R R Mero S S S S Most R result for each drug R R S
44 Cumulative Antibiogram QA Check Ensure individual AST results on pt. isolates are verified before being sent to database Report species with 30 isolates Define abbreviations Include appropriate drugs for the species Only those with breakpoints in CLSI M100 for the species Check footnotes (e.g., only ampicillin, a fluoroquinolone, TMP-SMZ, 3 rd gen cephalosporin, chloramphenicol for Salmonella / Shigella)
45 Cumulative Antibiogram QA Check (con t) Get 100% S for drug/bug combinations with only S breakpoints in CLSI M100 (e.g., Streptococcus pneumoniae and vancomycin) Staphylococcus - %S OX should = %S for other β-lactams (except amp, amox,, pen which should have a lower %S) Ensure results for related drugs make sense Compare data to previous year; account for significant changes Compare local data to national data
46 Trouble-Shooting N % Susceptible Imip Vanco K. pneumoniae S. aureus
47 Trouble-Shooting N % Susceptible Imip Vanco K. pneumoniae a - S. aureus b a Were there outbreaks with R strain (e.g., KPC producer)? b Are the 2% (16 isolates) that were VISA or VRSA accounted for?
48 Tools for examining statistical significance of %S Table H1. 95% confidence intervals for selected sample sizes CLSI M39-A3
49 How reliable is a report of 80% S for E. coli and ciprofloxacin? 95% Confidence Intervals for %S with Selected Sample Sizes Sample size % S CLSI M39-A3
50 Tools for examining statistical significance of %S Table H2. For comparing changes in %S CLSI M39-A3
51 If 80% of E. coli are susceptible to ciprofloxacin, what decrease in %S would be statistically significant (P 0.05)? # Isolates % S 80% % % CLSI M39-A3
52 Where can we find %S data from around the globe? Publications CDC / state Public Health Dept websites Pharmaceutical company websites EARRS Other Some examples follow!
60 Note: search for publications only
62 Summary (1) CLSI M39-A3 provides guidelines for preparation of a cumulative antibiogram to guide physicians in empiric therapy of initial infections. Cumulative antibiogram data are impacted by several factors to include: 1) culturing practices; 2) susceptibility testing policies; and 3) patient population served. The method used to exclude duplicate isolates on a given patient can impact cumulative antibiogram data. If drugs included in the cumulative antibiogram are only tested on select isolates,, data may be skewed.
63 Summary (2) It may be helpful to stratify %S data by one or more variables when developing empiric therapy guidelines for select patient populations, infections, etc. %S data for two drugs (e.g., %S to either of the two or both) may be helpful for guiding empiric therapy for suspected or confirmed infections caused by organisms generally treated with multiple agents. If the number of isolates is small,, the 95% confidence interval will be large. CLSI M39-A3 contains tools to help determine the statistical significance of changes in %S between time frames.
64 Summary (3) Each facility must customize cumulative antibiogram reports to optimize their use in that facility. There are several national and international sources of %S data. It is important to know source/nature of data used to construct the database when drawing conclusions. Although there are written guidelines for analysis and presentation of cumulative antimicrobial susceptibility test data, guidelines for use of these data are limited.
Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital
UNDERSTANDING YOUR DATA: THE ANTIBIOGRAM April Abbott, PhD, D(ABMM) Deaconess Health System Evansville, IN April.Abbott@Deaconess.com Special thanks to Dr. Shelley Miller for UCLA data WHAT WE WILL COVER
UNDERSTANDING THE ANTIBIOGRAM April Abbott, PhD, D(ABMM) Deaconess Health System Indiana University School of Medicine - Evansville Evansville, IN April.Abbott@Deaconess.com WHAT WE WILL COVER Describe
The Nuts and Bolts of Antibiograms in Long-Term Care Facilities J. Kristie Johnson, Ph.D., D(ABMM) Professor, Department of Pathology University of Maryland School of Medicine Director, Microbiology Laboratories
Antimicrobial Susceptibility Testing: Advanced Course Cascade Reporting Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to
2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose
VOLUME XXVII NUMBER 6 July 2012 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine B. Dowell SM, MLS (ASCP); Sarah K. Parker, MD; James K. Todd, MD Each year the Children s Hospital Colorado
Educating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges Janet Hindler, MCLS MT(ASCP) UCLA Medical Center firstname.lastname@example.org also working as a consultant with the Association
The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards Janet A. Hindler, MCLS, MT(ASCP) UCLA Health System Los Angeles, California, USA email@example.com 1 Learning Objectives Describe information
Multidrug-Resistant Organisms: How Do We Define them? How do We Stop Them? Roberta B. Carey, PhD Centers for Disease Control and Prevention Division of Healthcare Quality Promotion Why worry? MDROs Clinical
2010 ANTIBIOGRAM University of Alberta Hospital and the Stollery Children s Hospital Medical Microbiology Department of Laboratory Medicine and Pathology Table of Contents Page Introduction..... 2 Antibiogram
2017 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
RCH antibiotic susceptibility data The following represent RCH antibiotic susceptibility data from 2008. This data is used to inform antibiotic guidelines used at RCH. The data includes all microbiological
Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions
GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered
2015 Antibiogram Red Deer Regional Hospital Central Zone Alberta Health Services Introduction. This antibiogram is a cumulative report of the antimicrobial susceptibility rates of common microbial pathogens
INVITED ARTICLE MEDICAL MICROBIOLOGY L. Barth Reller and Melvin P. Weinstein, Section Editors Analysis and Presentation of Cumulative Antibiograms: ANewConsensusGuidelinefromtheClinicaland Laboratory Standards
BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016) VA Palo Alto Health Care System April 14, 2017 Trisha Nakasone, PharmD, Pharmacy Service Russell Ryono, PharmD, Public Health Surveillance
2016 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
2009 ANTIBIOGRAM University of Alberta Hospital and the Stollery Childrens Hospital Division of Medical Microbiology Department of Laboratory Medicine and Pathology 2 Table of Contents Page Introduction.....
Detecting / Reporting Resistance in Nonfastidious GNR Part #2 Janet A. Hindler, MCLS MT(ASCP) Methods Described in CLSI M100-S21 for Testing non-enterobacteriaceae Organism Disk Diffusion MIC P. aeruginosa
VOLUME XXIII NUMBER 1 July 2008 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell, SM (ASCP), Marti Roe SM (ASCP), Ann-Christine Nyquist MD, MSPH Are the bugs winning? The 2007
Antibiotic Abyss Fredrick M. Abrahamian, D.O., FACEP, FIDSA Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical Center Sylmar, California
Appendix A Intrinsic, implied and default resistance Magiorakos et al.  and CLSI  are our primary sources of information on intrinsic resistance. Sanford et al.  and Gilbert et al.  have been
AND QUANTITATIVE PRECISION (SAMPLE UR-01, 2017) Background and Plan of Analysis Sample UR-01 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony
Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide
VOLUME XXIX NUMBER 3 November 2014 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Marti Roe SM MLS (ASCP), Sarah Parker MD, Jason Child PharmD, and Samuel R.
جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی ویرایش دوم بر اساس ed., 2017 CLSI M100 27 th تابستان ۶۹۳۱ تهیه
EARS Net Report, Quarter 4 213 March 214 Key Points for 213* Escherichia coli: The proportion of patients with invasive infections caused by E. coli producing extended spectrum β lactamases (ESBLs) increased
Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory
Antimicrobial Susceptibility Patterns KNH SURGERY Department Masika M.M. Department of Medical Microbiology, UoN Medicines & Therapeutics Committee, KNH Outline Methodology Overall KNH data Surgery department
Dr Neeraj Goel Sr. Consultant Department of Clinical Microbiology Sir Ganga Ram Hospital Resistance profile of MDROs in ICU: Quinolone: 80% Amikacin: 75% Cefaperazone sulbactum: 79% Carbapenems: 79% Super
HUSRES Annual Report 2007 Martti Vaara www.huslab.fi www.intra.hus.fi The basis of this HUSRES 2007 report is the HUSLAB/Whonet database 2007, which contains susceptibility data on about 182.000 bacteria
Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate
Surveillance, Outbreaks, and Reportable Diseases, Oh My! Assisted Living Facility, Nursing Home and Surveyor Infection Prevention Training February 2015 A.C. Burke, MA, CIC Health Care-Associated Infection
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
What s next in the antibiotic pipeline? Jennifer Tieu, Pharm.D., BCPS Clinical Pearls OSHP Spring Meeting Mercy Hospital April 13, 2018 Objective 2 Describe the drug class and mechanism of action of antibiotics
Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates
655 West 12th Avenue Vancouver, BC V5Z 4R4 Tel 604.707.2443 Fax 604.707.2441 www.bccdc.ca Antimicrobial Resistance Trends in the Province of British Columbia 2013 Prepared by the Do Bugs Need Drugs? Program
POLQM Quality Conference firstname.lastname@example.org October 2 nd, 2017 Discuss the accuracy of results in microbiology, especially in susceptibility testing Review how well microbiology results are interpreted
National Surveillance of Antimicrobial Resistance Report to Ministry of Health by Sri Lanka College of Microbiologists SLCM ARSP & NLBSA Technical Committees December 2014 National Surveillance of Antimicrobial
Antimicrobial stewardship: Quick, don t just do something! Stand there! Stanley I. Martin, MD, FACP, FIDSA Director, Division of Infectious Diseases Director, Antimicrobial Stewardship Program Geisinger
Empiric Antibiotics for Pediatric Infections Seen in ED NOTE: Choice of empiric antibiotic therapy must take into account local pathogen frequency and resistance patterns, individual patient characteristics,
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 3 (2017) pp. 891-895 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.603.104
Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University
ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae Thomas Durand-Réville 02 June 2017 - ASM Microbe 2017 (Session #113) Disclosures Thomas Durand-Réville: Full-time Employee; Self;
Antibiotic Stewardship Program (ASP) CHRISTUS SETX Program Goals I. Judicious use of antibiotics Decrease use of broad spectrum antibiotics and deescalate use based on clinical symptoms Therapeutic duplication:
Rise of Resistance: From MRSA to CRE Paul D. Holtom, MD Professor of Medicine and Orthopaedics USC Keck School of Medicine SUPERBUGS (AKA MDROs) MRSA Methicillin-resistant S. aureus Evolution of Drug Resistance
Antibiotic Susceptibility Patterns of Community-Acquired Urinary Tract Infection Isolates from Female Patients on the US (Texas)- Mexico Border Yvonne Vasquez, MPH W. Lee Hand, MD Department of Research
Help with moving disc diffusion methods from BSAC to EUCAST This document sets out the main differences between the BSAC and EUCAST disc diffusion methods with specific emphasis on preparation prior to
Interpreting Microbiology reports for better Clinical Decisions Interpreting Antibiogrammes Prof C. Wattal Hon. Sr. Consultant & Chairman Dept. of Clinical Microbiology Sir Ganga Ram Hospital New Delhi
Guidelines for Treatment of Urinary Tract Infections Overview This document details the Michigan Hospital Medicine Safety (HMS) Consortium preferred antibiotic choices for treatment of uncomplicated and
Streptococcus pneumoniae Annual Report: 5 In 5, a total of, isolates of pneumococci were collected from 59 clinical microbiology laboratories across Canada. Of these, 733 (9.5%) were isolated from blood
VOLUME XXXII NUMBER 6 September 2017 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Stacey Hamilton MT SM (ASCP), Samuel Dominguez MD PhD, Sarah Parker MD, and
Multi-Drug Resistant Organisms Is Combination Therapy the Way to Go? Sutthiporn Pattharachayakul, PharmD Prince of Songkhla University, Thailand Outline Prevalence of anti-microbial resistance in Acinetobacter
Antimicrobial Stewardship Programs The Same, but Different Sara Nausheen, MD Kevin Kern, PharmD Antimicrobial Stewardship Programs The Same, but Different Objectives: Outline the overall function of an
The International Collaborative Conference in Clinical Microbiology & Infectious Diseases PLUS: Antimicrobial stewardship in hospitals: Improving outcomes through better education and implementation of
Multi-Drug Resistant Gram Negative Organisms POLICY REVIEW DATE EXTENDED 2018 Printed copies must not be considered the definitive version DOCUMENT CONTROL POLICY NO. IC-122 Policy Group Infection Control
Antibiotic Resistance Antibiotic Resistance: A Growing Concern Judy Ptak RN MSN Infection Prevention Practitioner Dartmouth-Hitchcock Medical Center Lebanon, NH Occurs when a microorganism fails to respond
ANTIMICROBIAL RESISTANCE IN KENYA; What Surveillance tells us Sam Kariuki Kenya Medical Research Institute Introduction Although no systematic national surveillance is in place, few sentinel studies indicate
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The
Implementation and Optimization of Antibiotic Stewardship in Acute Care Hospitals: A Clinical Microbiology Laboratory Perspective James E. Kirby, MD D(ABMM) Medical Director, Clinical Microbiology Beth
SMART WORKFLOW SOLUTIONS Introducing DxM MicroScan WalkAway System* The next-generation MicroScan WalkAway System combines proven technology and reliability with enhanced ease-of-use features to streamline
Interactive session: adapting to antibiogram Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe Case 1 63 y old woman Dx: urosepsis? After 2 d: intermediate result: Gram-negative bacilli Empiric antibiotic
Summary of the latest data on antibiotic resistance in the European Union EARS-Net surveillance data November 2017 For most bacteria reported to the European Antimicrobial Resistance Surveillance Network
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01
ESBL- and carbapenemase-producing microorganisms; state of the art Laurent POIREL Medical and Molecular Microbiology Unit Dept of Medicine University of Fribourg Switzerland INSERM U914 «Emerging Resistance
MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical
THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS Stefanie Desmet University Hospitals Leuven Laboratory medicine microbiology email@example.com
INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER University of Minnesota Health University of Minnesota Medical Center University of Minnesota Masonic Children s Hospital May 2017 Printed herein are
Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities. Gram-positive cocci: Staphylococcus aureus: *Resistance to penicillin is almost universal. Resistance
Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria
LEARNING OBJECTIVES ANTIMICROBIAL USES AND ABUSES Goodbye to the Antibiotic Era? Glenn D. Bedsole, MD, FACP Infectious Disease Consultant 1. Be able to list 6 examples of resistant bacteria that present
Antibiotics in the future tense: The Application of Antibiotic Stewardship in Veterinary Medicine Mike Apley Kansas State University Changes in Food Animal Antibiotic Use How the uses of antibiotics in
Approach to pediatric Antibiotics Gassem Gohal FAAP FRCPC Assistant professor of Pediatrics objectives To be familiar with common pediatric antibiotics o Classification o Action o Adverse effect To discus
Universidade de São Paulo Departamento de Moléstias Infecciosas e Parasitárias HEALTHCARE-ACQUIRED INFECTIONS AND ANTIMICROBIAL RESISTANCE Anna S. Levin 4 main lines! Epidemiology of HAS and resistance!
Fluoroquinolones in 2007: the Angels, the Devils, and What Should the Clinician Do? David C. Hooper, M.D. Division of Infectious Diseases Infection Control Unit Massachusetts General Hospital Harvard Medical
A retrospective analysis of urine culture results issued by the microbiology department, Teaching Hospital, Karapitiya LU Edirisinghe 1, D Vidanagama 2 1 Senior Registrar in Medicine, 2 Consultant Microbiologist,
ENTEROCOCCI April Abbott Deaconess Health System Evansville, IN OBJECTIVES Discuss basic antimicrobial susceptibility principles and resistance mechanisms for Enterococcus Describe issues surrounding AST
BC Children s Hospital and BC Women s Hospital & Health Centre CUMULATIVE ANTIBIOGRAM 2017 Division of Medical Microbiology Department of Pathology and Laboratory Medicine Page 1 of 5 GRAM-POSITIVE BACTERIA
Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.
New Antibiotics & New Insights into Old Antibiotics Louisiana Chapter of the American Academy of Pediatrics August 18, 2018 Baton Rouge, Louisiana John Bradley MD Rady Children s Hospital San Diego University
Hospital Acquired Infections in the Era of Antimicrobial Resistance Datuk Dr Christopher KC Lee Infectious Diseases Unit Department of Medicine Sungai Buloh Hospital Patient Story 23 Year old female admitted
Antimicrobial Susceptibility Testing: The Basics Susan E. Sharp, Ph.D., DABMM, FAAM Director, Airport Way Regional Laboratory Director, Regional Microbiology and Molecular Infectious Diseases Laboratories